41270-96-6
41270-96-6 結(jié)構(gòu)式
基本信息
4-碘-6-苯基嘧啶
MIF Antagonist III, 4-IPP
4-IODO-6-PHENYLPYRIMIDINE
Pyrimidine, 4-iodo-6-phenyl-
4-IPP (4-Iodo-6-phenylpyrimidine)
MIF Antagonist III, 4-IPP - CAS 41270-96-6 - Calbiochem
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-110063 | 4-IPP | 41270-96-6 | 1 mg | 237元 |
| 2026/06/05 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE 4-IPP | 41270-96-6 | 5mg | 660元 |
| 2026/06/05 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE 4-IPP | 41270-96-6 | 10mM * 1mLin DMSO | 726元 |
常見問題列表
| Target | Value |
|
MIF
() |
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .
Cell Cytotoxicity Assay
| Cell Line: | BMMs |
| Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
| Incubation Time: | 24 hours, 72 hours |
| Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: | BMMs |
| Concentration: | 5 μM,10 μM, 20 μM |
| Incubation Time: | 1 day, 3 days, 5 days |
| Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.
| Animal Model: | 8-weeks-old C57BL/6J male mice |
| Dosage: | 1 mg/kg, 5 mg/kg |
| Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
| Result: | Alleviated OVX-induced osteoporosis. |